H.C. Wainwright raises Xeris Biopharma Holdings' target price to $18 from $10
XERS•H.C. Wainwright raised its target price for Xeris Biopharma Holdings to $18 from $10.
Related News
Wells Fargo raises Globus Medical target price to $100 from $99
GMED•
Appian Corp: Morgan Stanley raises target price to $57 from $32
APPN•
Affirm Holdings price objective raised to $109 from $104 by BofA Global Research
AFRM•
Algonquin Power & Utilities Q3 2026 net earnings fall 19% to US$57.6 million
AQN•
Agomab Therapeutics director David R. Epstein reports $103,500 common share acquisition
AGMB•